key: cord-0001561-hww0watl
authors: Li, Wenchao; Jin, Hongyan; Sui, Xiukun; Zhao, Zhanzhong; Yang, Chenghuai; Wang, Wenquan; Li, Junping; Li, Gang
title: Self-Assembly and Release of Peste des Petits Ruminants Virus-Like Particles in an Insect Cell-Baculovirus System and Their Immunogenicity in Mice and Goats
date: 2014-08-12
journal: PLoS One
DOI: 10.1371/journal.pone.0104791
sha: 21469fd00f33c1dcdde68abf4b8da0508b7fe2d8
doc_id: 1561
cord_uid: hww0watl

Peste des petits ruminants (PPR) is an acute, febrile, viral disease of small ruminants that has a significant economic impact. For many viral diseases, vaccination with virus-like particles (VLPs) has shown considerable promise as a prophylactic approach; however, the processes of assembly and release of peste des petits ruminants virus (PPRV) VLPs are not well characterized, and their immunogenicity in the host is unknown. In this study, VLPs of PPRV were generated in a baculovirus system through simultaneous expression of PPRV matrix (M) protein and hemaglutin in (H) or fusion (F) protein. The released VLPs showed morphology similar to that of the native virus particles. Subcutaneous injection of these VLPs (PPRV-H, PPRV-F) into mice and goats elicited PPRV-specific IgG production, increased the levels of virus neutralizing antibodies, and promoted lymphocyte proliferation. Without adjuvants, the immune response induced by the PPRV-H VLPs was comparable to that obtained using equivalent amounts of PPRV vaccine. Thus, our results demonstrated that VLPs containing PPRV M protein and H or F protein are potential “differentiating infected from vaccinated animals” (DIVA) vaccine candidates for the surveillance and eradication of PPR.

Peste des petits ruminants (PPR) is a highly contagious and economically important viral disease of domestic and some wild small ruminants, and in particular, of goats and sheep. It is notifiable to the Office International des Epizooties (OIE). Clinically, the disease is characterized by severe pyrexia, oculonasal discharges, necrotizing and erosive stomatitis, enteritis, and pneumonia. It was first described in the Ivory Coast, West Africa, but has now become wide-spread in sub-Saharan Africa, Arabia, the Middle East, Southwest Asia, India, and other countries [1] . In China, PPR was first reported in Tibetin 2007 [2] , and in December 2013, a PPR outbreak was reported in Xinjiang Yili; in this outbreak,1236 goats were infected, of which 203 died, and6671 goats in the susceptible population were killed [3] . Thus, PPR outbreaks can cause severe economic losses, because they often result in high morbidity and mortality; therefore, development of an effective vaccine for the prevention and control of PPR is particularly important.

The causative agent, PPR virus (PPRV), is a member of the family Paramyxoviridae and the genus Morbillivirus [4] .The nonsegmented, single stranded, negative-sense RNA genome of PPRV encodes six structural proteins (nucleocapsid [N] , phosphoprotein [P] , matrix [M] , fusion [F], hemagglutinin [H] , and polymerase [L] proteins), and two non-structural proteins(C and V). Proteins N, P, and L are required for reconstituting viral RNA polymerase activity; M protein is required for particle formation and budding, and the two surface glycoproteins, H and F, are required for attachment and entry into the host cell. Structurally, the virions are morphologically pleomorphic particles that are surrounded by a host-derived membrane, modified by the H and F transmembrane glycoproteins, as well as the M protein, which is associated with the inner surface of the viral membrane [5, 6] .As in other paramyxoviruses, the C protein of PPRV is expressed from an alternative open reading frame (ORF) within the P gene, whereas the V protein is expressed by RNA editing [7] . These two proteins are thought to be involved in viral evasion of the host's immune responses, specifically by blocking interferon production during infection [8] .

For the control of PPR, four attenuated vaccines are available commercially. In endemic areas, the virus is currently controlled using the Nigeria 75/1 strain (Nig75/1), which has been attenuated by serial passage in Vero cells. In India, three other live attenuated vaccines are currently licensed for use: Sungri 96, Arasur 87, and Coimbatore 97 [9] . However, a major disadvantage of these attenuated vaccines is that they cannot be used for differentiating infected from vaccinated animals(DIVA).Recently, subunit vaccines have been developed based on the incorporation of PPRV immunogens into various vector systems, such as sheep or goat pox, vaccinia virus, adenovirus, or baculovirus vectors [10, 11, 12, 13] .

Virus-like particles (VLPs) recently emerged as alternatives to subunit vaccines; these have the advantage that they mimic the organization and conformation of the native virus capsid and envelope, but lack the viral genome [14, 15] .Given their intrinsic immunogenic properties and high safety profile, VLPs have been generated in different heterologous expression systems and have been tested as vaccine candidates for a variety of viral diseases [16] . In the human vaccines market, six VLP-based vaccines, including three for hepatitis B (Recombivax HB, Engerix B, and GenHevac B), two for human papillomavirus (Gardasil and Cervarix), and one for influenza A (InflexalV), have been developed [16, 17] .In the veterinary field, a VLP-based vaccine against porcine circovirus type 2 (PCV2), viz., Porcilis PCV, Intervet, has recently been licensed [18] .

To date, the assembly and release of PPRV VLPs have not been well characterized, and their immunogenicity remains unknown. It is known that the PPRV glycoproteins H and F contain neutralizing antibody epitopes and several T cell epitopes [19, 20] , and that PPRV-specific lympho proliferative responses can be elicited in goats immunized with a recombinant adenovirus expressing the H or F protein [10] . Therefore, we hypothesized that immunization with VLPs containing H or F proteins could induce a strong PPRV-specific immune response.

In this study, two types of VLPs for PPRV (PPRV-H and PPRV-F)were developed, using viral M protein co-expressed with H or F protein. Mice and goats immunized subcutaneously with these PPRV VLPs developed both humoral and cellular immune responses.

Cell culture and viruses PPRV vaccine strain (Nig75/1) was obtained from the China Institute of Veterinary Drug Control, Beijing, China. Vero cells (The American Type Culture Collection, ATCC: CCL-81, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle medium (DMEM; Invitrogen, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; Invitrogen, Grand Island, NY, USA) at 37uC with 5% CO 2 , and were used for PPRV propagation and titration. Spodoptera frugiperda Sf21 insect cells were maintained in Sf-900II insect serum-free medium (Invitrogen, Grand Island, NY, USA) as monolayer cultures or in suspension cultures maintained on temperate orbital shakers (120rpm) at 28uC.

Cloning of M, H, and F genes and construction of bacmid transfer plasmids PPRV RNA was extracted using Trizol LS (Invitrogen, Carlsbad, CA, USA). Reverse transcription(RT) and polymerase chain reaction (PCR) were performed on extracted viral RNA with gene-specific oligonucleotide primers( Table 1 ) that had been designed according to the sequence of the PPRV Nig75/1 strain (GenBank accession no. X74443.2).Following RT-PCR, the cDNA fragments containing the PPRV M, H, and F genes were cloned into the pMD18-T vector (Takara, Dalian, China). The integrity of the nucleotide sequences of the M, H, and F genes was verified by DNA sequencing.

The transfer plasmids were generated using the pFastBac Dual vector (Invitrogen, Grand Island, NY, USA), which contains two promoters. The M gene was cloned, as a1-kbXhoI-KpnIDNA fragment, downstream of the p10 promoter within the pFastBac-Dual bacmid transfer vector that had been digested with XhoI and KpnI. The resulting baculovirus transfer plasmid containing the PPRV M gene was designated p-M.

A bacmid transfer vector expressing both the M and H genes was prepared by cloning the H gene, as a 1.8-kb BamHI-HindIII DNA fragment, into the BamHI/HindIII sites downstream of the Autographacalifornica multiple nuclear polyhedrosis virus (AcMNPV) polyhedron(P H ) promoter in p-M. The resulting plasmid, p-MH, encoded the M and H genes downstream from the p10 and P H promoters, respectively.

Similarly, a bacmid transfer vector,p-MF, which permitted expression of both the M and F genes, was prepared by cloning the F gene, as a 1.6-kb BamHI-XbaI DNA fragment, downstream of the P H promoter, into p-M (Fig.1 ).

Recombinant bacmids were produced by site-specific transpositioning after transformation of bacmid transfer plasmids containing the PPRV genes into E.coli DH10Bac competent cells(Invitrogen, Carlsbad, CA, USA), which contained the AcMNPV baculovirus genome. The recombinant bacmids were identified by PCR using M13 primers together with gene-specific primers ( Table 1 ). The recombinant bacmid DNA was transfected into Sf21 insect cells using Cell Fectin II (Invitrogen, Grand Island, NY, USA), according to the Bac-to-Bac Expression Systems manual (Invitrogen, Grand Island, NY, USA). Briefly, a transfection mixture that contained 1 mg of recombinant bacmid DNA, 8mL of Cell fectinII, and 2 mL of unsupplemented Grace's Medium (Invitrogen, Grand Island, NY, USA), was prepared. Following incubation at room temperature for 30 min, the mixture was added to Sf21 insect cells, which had been seeded at 1610 6 cells per well, in 6-well plates. The transfection mixture and cells were incubated for 5 h at 28uC; the transfection mixture was then removed and 2 mL serum-free Sf-900II medium was added. The cultures were incubated at 28uC for 5 days and the supernatants were harvested as the first passage (P1) viral stock. Cells were continuously passaged in order to amplify baculovirus stock with the highest viral titer. The recombinant baculovirus stock was titrated by agarose plaque assay on Sf21 insect cell cultures in 6-well plates.

To produce PPRV-H VLPs, Sf21 insect cells were infected in a 200-mL volume, at a cell density of 2610 6 cells per mL, with rBVs expressing PPRV H and M proteins, at a multiplicity of infection (MOI)of 4. Similarly, PPRV-F VLPs were produced by infecting Sf21 insect cells with rBVs expressing the PPRVF and M proteins. Cell culture supernatants were harvested 3 days post-infection, cleared by low-speed centrifugation (20006g,30 min at 4uC)to remove cells, and VLPs in the supernatants were then pelleted by ultracentrifugation using a SorvallT1250 rotor (100,0006g, for 1 h, at 4uC). The resulting pellets were dissolved in 2 mL of phosphate-buffered saline solution (PBS, pH7.2), and were then further purified through a discontinuous sucrose gradient (20-30-60% w/v, in PBS) and sedimented by ultracentrifugation in a SorvallTH641 swinging bucket rotor (100,0006g, for 3 h, at 4uC). As a control, we used the PPRV Nig75/1 virus. The visible opalescent bands in the sucrose gradient were collected, diluted in PBS, and pelleted by centrifugation in a Sorvall T1250 rotor (100,000 6g, for 2 h, at 4uC) to remove the sucrose. The sedimented particles were resuspended in PBS and stored at 4uC. The concentration of the VLPs was determined using a bicinchoninic acid protein assay kit (BCA protein assay kit; Beyotime, Shanghai, China).

To detect the protein reactivity of VLPs, purified VLPs were boiled for 5 min in reducing Laemmli sample buffer and resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and then transferred to a polyvinylidene difluoride membrane by electroblotting (Bio-Rad, Hercules, CA, USA). The membrane was blocked with 5% dried non-fat milk in PBST (0.05% Tween-20 in PBS), overnight at 4uC, and then incubated with goat serum against PPRV (diluted 1:200 in blocking buffer), for 1 h at 37uC. The membrane was washed three times with PBST, for 5 min each time, and then incubated with horseradish peroxidase (HRP)conjugated rabbit anti-goat IgG antibody (diluted 1:2000 in blocking buffer; Zhongshanjinqiao, Beijing, China). Following several washes with PBST, the specific bands were detected using the substrate 3,39-diaminobenzidine tetrahydrochloride (Tiangen, Beijing, China) for 5 min at room temperature. The reaction was stopped with water and membranes were photographed.

To examine budding of VLPs, Sf21 insect cells that had been infected with rBVs expressing the M and H/F proteins were fixed with 0.25% glutaraldehyde and 1% osmium tetraoxide, dehydrated with ethanol, and then embedded in SPI-PON 812 resin (Structure Probe, West Chester, PA, USA). Thin sections were stained with lead citrate and uranyl acetate and then observed by electron microscopy [21] .

The presence and morphology of the purified VLPs and PPRV were evaluated by TEM of negatively stained preparations. A carbon-coated grid was set on a 20-mL sample drop for 10 min, and washed with deionized water. Washed samples were negatively stained with 1% uranyl acetate at pH 4.5. Excess stain was removed using filter paper, and the grids were observed at magnifications ranging from 60,0006 to 200,0006 on a transmission electron microscope (H-7500, Hitachi, Tokyo, Japan) operating at 80 kV.

The designs of the animal experiments are shown in Table 2 .

The animal experiments were conducted with prior approval from the Animal Care and Use Committee of Chinese Academy of Agricultural Sciences, China. All animal experiments were carried out in accordance with the requirements of the Regulations of Experimental Animal Administration of the PR China. All efforts were made to minimize suffering. The proteins that were used to vaccinate animals were purified by sucrose gradient ultracentrigugation and the concentration was determined by using a BCA protein assay kit (BCA protein assay kit; Beyotime, Shanghai, China).

For mouse experiments, female inbred BALB/c mice (Vital River, Beijing, China), aged 6 to 8 weeks, were randomly divided into seven groups (n = 10 for each group). Mice were immunized subcutaneously (s.c.) with different amounts (10 or 40 mg total protein per mouse) of PPRV VLPs or PPRV Nig75/1diluted in 100mL of PBS. All groups received a booster injection of the original dosage at 4 weeks after the primary immunization. No adjuvant was used for any of the mice. Blood samples were collected by retro-orbital plexus puncture, at various time-points. After the blood samples were allowed to clot and then centrifuged, serum samples were collected and stored at 220uCuntil required for antibody titration.

For goat experiments, 20 outbred goats (6-24 months of age) were randomly divided into four groups of five each, and housed separately. None of the goats had detectable levels (titers less than1:5) of PPRV neutralizing antibodies. Groups 1 and 2 were vaccinated subcutaneously with 300 mg PPRV-H or PPRV-F VLPs diluted in 1 mL of PBS, respectively. Group 3 goats were inoculated with 1 mL PPRV Nig75/1(10 5.5 TCID 50 ), as positive control. Group 4 goats were inoculated subcutaneously with 1 mL PBS as negative control. Booster vaccination was performed using the same dose, at 3 weeks after primary immunization. Serum samples were collected at various time-points post-immunization, and stored at 220uC until analyzed.

Sera from immunized and control mice were analyzed for PPRV-specific antibodies (IgG, IgG1, and IgG2a) by indirect ELISA. Briefly, 96-well flat-bottomed plates were coated with 100mLof purified PPRV whole-virus antigen at a concentration of 2 mg/mL per well in 0.1 M carbonate/bicarbonate coating buffer (pH 9.6),overnight at 4uC, and then the plates were blocked with 5% skim milk in PBST, for 2 h at 37uC. Serum samples, serially diluted in PBST, were added to the wells, in duplicate, and incubated at 37uC for 1 h. After washing with PBST three times, each well received 100mL of a 1/4000-diluted HRP-labeled goat anti-mouse IgG, IgG1, and IgG2a (Southern Biotech, Birmingham, AL, USA) and incubated at 37uC for 1 h. Finally, after washing with PBST three times, 100 mL of freshly prepared tetramethylbenzidine (Tiangen, Beijing, China) solution was added to each well and color was allowed to develop for 10 min, before stopping the reaction with 100mL of 2 M H 2 SO 4. Optical density (OD) values were measured at a wavelength of 450 nm using an ELISA microplate reader (Multiskan Ascent; Thermo, Vantaa, Finland). The mean titers were calculated from log 10 of the highest serum dilution that yielded a two-fold higher OD value compared to that of sera from PBSvaccinated mice.

All serum samples from immunized mice and goats were analyzed for the detection of PPRV-specific virus neutralization antibody (VNA) titers using a micro-neutralization assay, according to the 2013 OIE terrestrial manual [22] . Briefly, serum samples were complement-inactivated at 56uC for 30 min and were then serially diluted two-fold (mice sera, from 1:4; goat sera, from 1:5) Table 2 . Experimental designs used for the animal studies. in cell culture medium. The diluted sera (100mL) were mixed with an equal volume of PPRV (1000TCID 50 /mL) in a 96-well cell culture plate and incubated at 37uC for 1 h; then, 50mL of Vero cell suspension was added to each well and the cells were cultured at 37uC in the presence of 5% CO 2 .A series of control wells for virus and uninfected cells were also included. Cells were observed for a cytopathic effect (CPE) by microscope at day 8 after incubation, and the VNA titer was calculated. VNA titer was defined as the highest dilution of the test serum at which the CPE was inhibited by at least 50%.

Three mice from different groups were sacrificed at 7 days after booster immunization and splenocyte suspensions were prepared as previously described [23] . Splenocytes were seeded in 96-well flat-bottom plates at a density of 2610 6 cells per well in RPMI1640 medium (Invitrogen, Grand Island, NY, USA) containing 10% FBS. Splenocytes were stimulated in vitro with 50mL of UVinactivated PPRV Nig75/1(10 4 TCID 50 ). Concanavalin A (Sigma-Aldrich, St. Louis, MO, USA) was used as positive control, and medium was used as negative control. After 3 days' incubation at 37uC in a 5% CO 2 atmosphere, the proliferative response was determined using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay, using the Cell Titer 96 Aqueous One Solution Cell Proliferation kit (Promega, Madison, WI, USA), following the manufacturer's instructions. The lymphocyte proliferation rate was quantified using the stimulation index (SI), which was calculated as the ratio of the OD 490 of the stimulated cells to the OD 490 of the negative controls.

Goats were bled via jugular vein puncture at week 2 after the booster injection. Peripheral blood mononuclear cells were prepared as previously described [10] . Cells(2610 5 cells per well) were plated in 96-well plates and stimulated with inactivated PPRV Nig75/1 for 72 h at 37uC under 5% CO 2 . Unstimulated cells, cultured in medium alone, were used as negative control. The proliferative response was determined by MTS assay, as described above. Interferon (IFN)-cELISPOT assays Splenocytes from inoculated mice were obtained and plated at a density of 2610 5 cells per well in a 96-well ELISpot plate, which had been coated with IFN-c. One hundred microliters of inactivated PPRV Nig75/1was added as stimulus. The cultures were then incubated in a 37uC humidified incubator, with 5% CO 2 , for 16 h, and then spots were detected as per the manufacturer's instructions (Mabtech, Nacka, Sweden).

The data were analyzed with one-way ANOVA in GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA, USA); pvalues less than 0.05 were considered statistically significant.

The open reading frames of PPRV M, H, and F genes from PPRV strain Nig75/1 were amplified by RT-PCR and sub-cloned into pFastBacDual vectors (Fig.1 ).The insertion of the genes into the expression vector was confirmed by enzyme digestion analysis and DNA sequencing. The rBVs were generated after transfection of Sf21 insect cells with recombinant bacmids. The titers of rBVs-PPRV MH and rBVs-PPRV MF were titrated in a plaque-forming assay, and exhibited titers of 3.5610 7 and 4.7610 7 PFU/ml, respectively, at the third passage.

PPRV-H VLPs and PPRV-F VLPs were produced and purified as described in the Materials and Methods section. The VLPs bands were mainly distributed between 30% and 60%sucrose in the gradient after ultracentrifugation ( Fig.2A) . Electron microscopic examination of negatively stained samples revealed that both PPRV-H and PPRV-F VLPs showed spherical shapes, with spikes on their surfaces, and with a diameter of approximately 80-100 nm, which is similar to the morphology and size of native PPRV particles propagated in Vero cells (Fig.2E-G ).An ultrathin section of Sf21 insect cells infected with rBVs at 48-h post-infection was investigated, revealing VLPs with a diameter of approximately 100 nm budding from the plasma membrane, and some spikeless VLPs distributed throughout the cytoplasm (Fig. 2B-C) .

Incorporation of the H or F proteins, as well as M protein, into VLPs was confirmed by western blotting using anti-PPRV antibodies, by the presence of 37 kDa, 70 kDa, and 70 kDa bands, corresponding to the M, H, and F proteins, respectively, on the blots (Fig.3) . The sizes of the M and H proteins corresponded to those predicted from the deduced protein sequences, but the F protein band derived from VLPs differed from the form of PPRV particles propagated in mammalian cells. In the mammalian cell expression system, the F protein is synthesized as a precursor (F0) of about 60 kDa; after translation, F0 is glycosylated and cleaved to yield a 46-kDa (F1) and 25-kDa (F2) disulfide-link-competent F protein. In the baculovirus-insect cell expression systems, the PPRV F protein was generated as a 70-kDa band in the western blot membrane, indicating that the F protein was not cleaved and was generated as the F0 precursor, which was also glycosylated. In total, the amount of the expressed VLPs was about 3-4.5 mg/L in the cell culture medium.

The specific antibody responses of mice immunized with PPRV-H VLPs or PPRV-F VLPs were determined by indirect ELISA.

The levels of total PPRV-specific IgG in the serum after primary and booster vaccinations were determined; the results are shown in Fig.4 . Total IgG titers in all groups of mice immunized with VLPs or PPRV were higher after the booster than after the primary vaccination, indicating that booster immunization could stimulate the immune memory cells and induce an anamnestic response, promoting antibody production and exaltation. When mice were immunized with a lower antigen dose of 10 mg, total IgG titers of mice immunized with PPRV-H VLPs were significantly higher than those of mice immunized with PPRV-F VLPs or PPRV after the primary vaccination, indicating that the titers of antibodies against PPRV-H VLP proteins increased faster than the titers of antibodies against PPRV-F VLPs or PPRV. The maximal titers detected in both VLP-and virus-immunized mice were similar after the booster vaccination. Similar patterns of total IgG responses were found in mice immunized with 40 mg VLPs or PPRV. PPRV-specific serum antibodies of IgG1 and IgG2a were also evaluated by ELISA. These results demonstrated that mice immunized with PPRV-H VLPs and PPRV using a lower dose of antigen (10 mg) induced high IgG1 serum antibody titers(1:1000 to 1:2400), and lower specific IgG2a serum antibody titers(1:200 to 1:250) after the first immunization. In contrast, the levels of IgG1 antibody responses were lower (1:200) ,and the IgG2a responses were higher (1:700),in mice immunized with PPRV-F VLPs relative to those observed in mice immunized with PPRV-H VLPs or PPRV. The levels of IgG1 and IgG2a from all three immunized groups of mice increased after the booster immunization (Fig.5A) . Similar patterns of IgG1 and IgG2a responses, as well as IgG1:IgG2a ratios, were found in mice immunized with 40 mg VLPs or PPRV (Fig.5B) .

Taken together, the data indicated that immunization with PPRV-H VLPs induced predominantly specific IgG1 serum antibodies, favoring the stimulation of a T-helper class 2(Th-2) immune response against PPRV, while immunization with PPRV-F VLPs induced a stronger Th-1 immune response, despite the use of a lower immunization dose.

Since the neutralizing activity against PPRV is an indicator of functional antibodies that confer protective immunity, we investigated whether mice and goats immunized with PPRV VLPs could produce neutralizing antibodies, using a micro-neutralization assay. Serially diluted sera from various time-points postimmunization were complement-inactivated, and incubated with live PPRV Nig75/1; the CPE assays were conducted in Vero cells. As shown in Table3, PPRV-H or PPRV-F VLPs-vaccinated mice developed VNA, and the titers ranged from 1:32 to 1:64 and from 1:16 to 1:32, after booster immunization. As shown in Table 4 , at 2 weeks after primary immunization, the titers of VNA in the PPRV-H VLPs-and PPRV-vaccinated goat groups exceeded 10, a number that represents a margin considered to be protective in goats vaccinated with live attenuated PPRV vaccines [22] . Moreover, this value was significantly enhanced after the booster immunization and reached values of 80-160; these high VNA titers were maintained for at least 6 weeks, and decreased gradually from 15 weeks after primary immunization. The titer of the PPRV-F VLPs group was lower compared to that of the PPRV-H VLPs-and PPRV-vaccinated goat groups. However, 2weeks after the booster immunization, all the goats that had been immunized with PPRV-F VLPs showed VNA titers above 10.

Taken together, the data of the mouse and goat vaccination experiments showed that serum VNA levels were significantly higher in the PPRV-H VLPs-immunized group than in the PPRV-F VLPs-immunized group, and were comparable to that of the whole virus-immunized group. No neutralization activity against PPRV was detected when using pre-immune serum or in the sera of experimental animals injected with PBS.

To investigate the cell-mediated immune responses induced by VLPs, the lymphocyte proliferation response of mice was analyzed after the booster immunization. As shown in Table3, compared with the PBS control group, mice immunized with VLPs or PPRV exhibited significantly stronger lymphocyte proliferation responses (P,0.05). As shown in Table4, the data from the lymphocyte proliferation assay of goats from the three groups immunized with PPRV-H VLPs, PPRV-F VLPs, or attenuated PPRV indicated similarly strong cellular immune responses. There was no significant difference among mice immunized with different concentrations of VLPs or PPRV (P.0.05).

We also evaluated the mounting of PPRV-specific T-cell responses in vaccinated mice. Splenocytes, obtained at 7days after the booster immunization, were cultured in the presence of inactivated PPRV, and IFN-c production was measured by ELISPOT assays (Fig.6 ). Both PPRV-H VLPs-and PPRV-F VLPs-vaccination induced specific IFN-c production in response to PPRV exposure; the frequency of cells secreting IFN-c positively correlated with the immunization dose. No specific production of IFN-c in response to PPRV exposure was detected in control mice inoculated with PBS.

Altogether, these data demonstrated that inoculation with PPRV-H VLPs and PPRV-F VLPs can generate specific T-cells that recognize the PPRV H and F proteins in vivo.

The minimum molecular requirement for efficient assembly and release of PPRV virions is still unknown. In this study, we found that the major structural genes of PPRV can be efficiently expressed in recombinant baculovirus-infected Sf21 insect cells and that these genes can then support the production of PPRV VLPs. The expression of M protein was necessary and sufficient for the formation of VLPs (data not shown); the additional expression of the H or F glycoproteins allowed formation of budding particles with the typical morphology and size of PPRV and related paramyxoviruses. A recent study demonstrated that PPRV spikeless VLPs could be formed by co-expression of the M and N proteins in insect cells; however, expression of M protein alone in insect cells did not result in VLP formation, as assessed by TEM [24] , which was contrary to our results. The finding that M protein alone could be released from cells and generate VLPs has also been observed for some other paramyxoviruses, including human parainfluenza virus type1 [25] , Sendai virus [26] , Newcastle disease virus [27] , and Nipha virus [28] , as well as for viruses in other related virus families, including Ebola [29] and vesicular stomatitis virus [30] .In addition, some paramyxovirus M proteins, such as parainfluenza virus type5 [31] and mumps virus [32] , lack the ability to direct efficient VLP production when expressed alone in cells, but VLP production becomes highly efficient when M proteins are expressed together with other viral proteins. Hence, although the requirements for efficient VLP production differ among paramyxoviruses, it appears as if, in general, M protein is the major requirement for paramyxovirus VLP production, as VLPs cannot be formed in its absence [6, 33] . The baculovirus expression vector-insect cell system has been utilized extensively for VLP production, and particularly for production of enveloped VLP vaccines [34, 35, 36] . Baculovirus expression of heterologous genes permits multiple post-translational modifications, like folding, oligomerization, phosphorylation, glycosylation, acylation, disulfide bond formation, proteolytic cleavage, and so on, which are similar or identical to those that occur in mammalian cells. However, in this study, the molecular size of the expressed F protein was 70 kDa, but the F protein was cleaved into F1 and F2 protein upon expression in mammalian cells; the results indicated that there are differences in the posttranslational modification in the two expression systems. Furthermore, insect cells are able to grow in serum-free medium cultures; this is highly desirable, because serum may be a cause of adventitious viruses. Therefore, its use requires more intensive purification processes to remove serum proteins. Additionally, these cells are perfectly adapted to suspension conditions, allowing for large-scale culture [37, 38] . These advantages make the baculovirus expression vector-insect cell system a promising platform for production of VLPs [39] .

In this study, we chose the pFastBacDual (Invitrogen) baculovirus transfer vector, which contains two promoters, so that insect cells infected with a single recombinant bicistronic baculovirus could express two proteins concurrently. The coexpression strategy is particularly important for the efficient assembly of multi-protein complexes, where simultaneous expression of multiple viral proteins is essential [40] .Co-expression and co-infection strategies have previously been compared in the production of triple-layered rotavirus VLPs(VP2,VP6, and VP7), and SARS VLPs. For production of rotavirus VLPs, co-expression was more efficient than co-infection [41] . SARS VLPs could not be generated in Sf9 cells co-infected with three recombinant viruses expressing the M, E, and S proteins, but spontaneous assembly of highly stable VLPs occurred when using a single recombinant baculovirus expressing all three SARS proteins simultaneously [35] .

The main limitation of the baculovirus expression vector-insect cell system is the co-production of recombinant baculoviruses (enveloped viruses) during the infection process; thus, when developing PPRV VLP vaccines, the challenging task is the Table 4 . Peste des petitsruminants virus (PPRV) neutralizing antibody titers and lymphocyte proliferation responses in goats immunized with PPRV virus-like particles (VLPs) or native PPRV particles. purification of VLPs from the recombinant baculoviruses, which share a similar density and enveloped structure [39, 42] . In our study, although purification was possible by centrifugation in sucrose density gradients, residual baculoviruses were consistently detected in VLP preparations (Fig. 2D) .Given the safety concerns, VLPs should be purified via chemical (binary ethylenimine) or physical(UV irradiation) inactivation treatments, to eliminate any possible baculovirus infectivity when considering clinical trials. For many viruses, recombinant VLPs have been shown to yield promising vaccines, because of their robust immunogenicity, elicitation of protective neutralizing antibodies (due to the presence of conformational epitopes on VLPs), and their safety profiles (as they do not contain any viral genetic material). In this study, the effectiveness of PPRV VLPs as an immunogen was demonstrated in mice and goats. The results indicated that high specific antibody titers against PPRV could be induced by both PPRV-H VLPs and PPRV-F VLPs, which were as high as those resulting from immunization with PPRVNig75/1. The VNA titers elicited by PPRV-H VLPs were much higher than those induced by PPRV-F VLPs, and the VNA titers of PPRV-H VLPs were as high as the responses to the attenuated virus vaccine. Previous reports have shown that the H protein of PPRV is a more potent inducer of high VNA titers than the F protein [11] , while the F protein seems to induce mainly a cellular immune response [43] .Our results demonstrated that mice immunized with PPRV-H and PPRV-F VLPs exhibited a similarly high level of cell-mediated immune responses.

We further showed that subcutaneous immunization of mice with PPRV-H VLPs at a dose of 10 mg, in the absence of adjuvant, induced strong humoral immune responses. This immunogenicity is related to the structural features of the VLPs, which are particulate structures that contain a dense and repetitive pattern of epitopes on their surfaces. In contrast, monovalent, non-particulate antigens do not always reflect the native structure of the protein, and the related antibody responses are not always specific for physiologically relevant epitopes. Consequently, administration of these vaccines often requires use of strong adjuvants, as well as large and frequent doses of the antigen. In contrast, VLP-based vaccines are strongly immunogenic, often reducing or eliminating the need for exogenous adjuvants [44, 45] . An additional benefit of this VLP-vaccination approach is that it may allow improved surveillance through DIVA, as seroconversion to N protein will occur only in animals that have been infected with PPRV, but not in VLP-vaccinated animals that have not been infected. A commercially available N protein-based competitive ELISA kit might strengthen the usefulness of VLP vaccines [46] . We also detected PPRV-specific antibodies in the vaccinated goats, using an N protein-based competitive ELISA established in our laboratory. No N protein-specific antibodies were found in goats vaccinated with PPRV H or PPRV F VLPs; in contrast, seroconversion to N protein was detected in goats vaccinated with the PPRV Nig 75/1 attenuated virus (data not shown).

To our knowledge, this is the first report that demonstrated the construction of PPRV VLPs consisting of immunogenic proteins and that assessed their immunogenicity in two animal models, viz., mice and goats. Taken together, the results of our study suggested that PPRV VLPs can be generated in insect cells simultaneously expressing the PPRV M protein with H or F protein. The VLPs had a morphology and size similar to those of native virus particles. Humoral and cellular immunity against PPRV were efficiently induced in mice and goats vaccinated with these PPRV VLPs, without the need for adjuvants. Thus, PPRV-H VLPs or PPRV-F VLPs may be promising vaccine candidates for PPR, and DIVA tests may prove of great benefit in future control programs for this disease. . Specific interferon (IFN)-cproduction in response to peste des petits ruminants virus (PPRV) proteins in splenocytes from mice, as detected by ELISPOT assay. Splenocytes from mice inoculated with PPRV virus-like particles (VLPs), PPRV per se, or phosphate-buffered saline (PBS) were isolated and cultured for 16h in the presence of inactivated PPRV. The production of IFN-cwas measured using an ELISPOT assay. Samples were tested in triplicate and mean IFN-cvalues for each mouse are shown. doi:10.1371/journal.pone.0104791.g006

Global distribution of peste des petits ruminants virus and prospects for improved diagnosis and control

Peste des petits ruminants virus in Tibet

/12/2013: Peste des petits ruminants, (People's Rep. of China)

Classification of peste des petits ruminants virus as the fourth member of the genus Morbillivirus

The molecular biology of the morbillivirus (measles) group

Molecular mechanism of paramyxovirus budding

Paramyxoviridae: the viruses and their replication

Morbillivirus v proteins exhibit multiple mechanisms to block type 1 and type 2 interferon signalling pathways

Comparative efficacy of peste des petits ruminants (PPR) vaccines

Recombinant adenovirus expressing F and H fusion proteins of peste des petits ruminants virus induces both humoral and cell-mediated immune responses in goats

A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep

MVA recombinants expressing the fusion and hemagglutinin genes of PPRV protects goats against virulent challenge

Baculovirus display of fusion protein of Peste des petits ruminants virus and hemagglutination protein of Rinderpest virus and immunogenicity of the displayed proteins in mouse model

Virus-like particles: promising platforms with characteristics of DIVA for veterinary vaccine design

Current strategies for subunit and genetic viral veterinary vaccine development

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

One dose of a porcine circovirus 2 subunit vaccine induces humoral and cellmediated immunity and protects against porcine circovirus-associated disease under field conditions

Immune responses in goats to recombinant hemagglutinin-neuraminidase glycoprotein of Peste des petits ruminants virus: identification of a T cell determinant

Mapping of B-cell epitopic sites and delineation of functional domains on the hemagglutinin-neuraminidase protein of peste des petits ruminants virus

Human annexin A6 interacts with influenza a virus protein M2 and negatively modulates infection

Manual of diagnostic tests and vaccines for terrestrial animals

Immune responses in mice vaccinated with a suicidal DNA vaccine expressing the hemagglutinin glycoprotein from the peste des petits ruminants virus

Formation of peste des petits ruminants spikeless virus-like particles by co-expression of M and N proteins in insect cells

Human parainfluenza virus type 1 matrix and nucleoprotein genes transiently expressed in mammalian cells induce the release of virus-like particles containing nucleocapsid-like structures

Role of matrix and fusion proteins in budding of Sendai virus

Requirements for the assembly and release of Newcastle disease virus-like particles

Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein

Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP

Viral liposomes released from insect cells infected with recombinant baculovirus expressing the matrix protein of vesicular stomatitis virus

Requirements for budding of paramyxovirus simian virus 5 virus-like particles

Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles

Paramyxovirus assembly and budding: building particles that transmit infections

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

Efficient assembly and release of SARS coronaviruslike particles by a heterologous expression system

Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens

A kinetic and statistical-thermodynamic model for baculovirus infection and virus-like particle assembly in suspended insect cells

Recombinant protein vaccines produced in insect cells

Use of baculovirus expression system for generation of virus-like particles: successes and challenges

Coexpression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks

Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production

Influenza viruslike particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice

Development of a dual recombinant vaccine to protect small ruminants against peste-des-petits-ruminants virus and capripoxvirus infections

Assembly and biological and immunological properties of Newcastle disease virus-like particles

Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs

Development of a competitive ELISA for detecting antibodies to the peste des petits ruminants virus using a recombinant nucleoprotein

We thank the Electron Microscopy Core Facility of the Institute of Agroproducts Processing, Science, and Technology, CAAS, for TEM analysis. We also thank Dr. Huailiang Ma for kindly editing this manuscript.

Conceived and designed the experiments: WL GL. Performed the experiments: WL XS. Analyzed the data: WL ZZ HJ. Contributed reagents/materials/analysis tools: JL CY WW. Wrote the paper: WL ZZ. Requested financial support: GL.